When it comes to the question of which biotech companies could be the next M&A targets, one analyst cited in today’s article says the “easy answer” is oncology companies, as the oncology subsector has seen an outsized share of M&A activity. But which specific oncology-focused biotechs are possible M&A targets? For a look at two that could potentially be bought up – and what makes them so attractive – CLICK HERE.